Pharmacoeonomic evaluation of secondary prophylaxis of acute coronary syndrome by statins in Ukraine

Abstract

OBJECTIVES: In Ukraine cardiovascular diseases occupy a leading place in the structure of death rate (25,9 %) and are one of most reasons of country depopulation. From data of evidence-based medicine application of hypolipidemic preparations of statins in complex therapy of cardiovascular diseases and for the prophylaxis of their complications assists the decline of both common and cardiovascular death rate. The aim of this research is a choice the optimal preparations from the statins for the secondary prophylaxis of acute coronary syndrome on the basis of cost-minimization analysis results in Ukraine. METHODS: Cost-minimization analysis of hypolipidemic therapy with statins for the secondary prophylaxis of acute coronary syndrome. The objects are results of a few meta-analyses and multicentral clinical trials: STELLAR, MERCURY, GREACE, 4S (Scandinavian Simvastatin Survival Study); preparations of statins presented at the pharmaceutical market of Ukraine. The prices on preparations were taken from the price-lists (October, 2010). RESULTS: The analysis of meta-analyses and multicentral clinical trials results of atorvastatin, simvastatin and rosuvastatin preparations showed that these preparations have practically equal clinical effectiveness for the secondary prophylaxis of acute coronary syndrome. The results of _cost-minimization_ analysis showed that the costs for preparations of atorvastatin were less than the costs for preparations of simvastatin and rosuvastatin. The hypolipidemic therapy with rosuvastatin are the most expensive. The costs for the course of prophylaxis by preparations of simvastatin are less, than the costs for the course of prophylaxis by rosuvastatin and more, than the costs for prophylaxis by atorvastatin. CONCLUSIONS: Generic preparations of atorvastatin are the least expense among others statins presented at the pharmaceutical market of Ukraine, and remain preparations of choice for the prophylaxis of acute coronary syndrome.